AR108829A1 - Vacuna contra virus de bronquitis infecciosa - Google Patents

Vacuna contra virus de bronquitis infecciosa

Info

Publication number
AR108829A1
AR108829A1 ARP170101649A ARP170101649A AR108829A1 AR 108829 A1 AR108829 A1 AR 108829A1 AR P170101649 A ARP170101649 A AR P170101649A AR P170101649 A ARP170101649 A AR P170101649A AR 108829 A1 AR108829 A1 AR 108829A1
Authority
AR
Argentina
Prior art keywords
orf
subject
infectious bronchitis
bronchitis virus
vaccine against
Prior art date
Application number
ARP170101649A
Other languages
English (en)
Inventor
Egbert Mundt
Monique Verheije
Beurden Stefanus Van
Petrus Rottier
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of AR108829A1 publication Critical patent/AR108829A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20062—Methods of inactivation or attenuation by genetic engineering

Abstract

Un IBV (virus de bronquitis infecciosa) y una composición inmunogénica que comprende un IBV, respectivamente, en donde el ORF 3a y/o el ORF 3b y/o el ORF 5a y/o el ORF 5b está inactivado. Métodos para inmunizar a un sujeto que comprende la administración a un sujeto de la composición inmunogénica de la presente. Más aún, métodos de tratamiento o de prevención de signos clínicos causados por IBV en un sujeto que lo necesita, que comprende la administración al sujeto de una cantidad terapéuticamente eficaz de una composición inmunogénica.
ARP170101649A 2016-06-16 2017-06-15 Vacuna contra virus de bronquitis infecciosa AR108829A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16174857 2016-06-16

Publications (1)

Publication Number Publication Date
AR108829A1 true AR108829A1 (es) 2018-10-03

Family

ID=56148179

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101649A AR108829A1 (es) 2016-06-16 2017-06-15 Vacuna contra virus de bronquitis infecciosa

Country Status (12)

Country Link
US (1) US11065328B2 (es)
EP (1) EP3471769A1 (es)
JP (1) JP6874023B2 (es)
KR (1) KR20190021334A (es)
CN (1) CN109641043A (es)
AR (1) AR108829A1 (es)
BR (1) BR112018076234A2 (es)
CO (1) CO2019000214A2 (es)
EA (1) EA201990010A1 (es)
IL (1) IL263550A (es)
MX (1) MX2018015506A (es)
WO (1) WO2017216180A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6874023B2 (ja) 2016-06-16 2021-05-19 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 伝染性気管支炎ウイルスに対するワクチン
EA202191147A1 (ru) * 2018-10-31 2021-08-23 Бёрингер Ингельхайм Ветмедика Гмбх Вакцина виб h52 с гетерологичным шиповидным белком
JP7206383B2 (ja) * 2018-10-31 2023-01-17 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 異種スパイクタンパク質を有する４／９１ ｉｂｖワクチン
CN110467671B (zh) * 2019-07-04 2022-08-23 中崇信诺生物科技泰州有限公司 一种用spf鸡制备tw1型鸡传染性支气管炎病毒阳性血清的方法
CN111893212A (zh) * 2020-06-17 2020-11-06 安徽农业大学 猫传染性腹膜炎病毒实时荧光定量pcr引物组及试剂盒
CN112048006B (zh) * 2020-09-08 2021-04-27 扬州大学 一种替代中和效力测定的elisa方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
DK1259257T3 (da) 2000-02-29 2010-06-14 Wyeth Llc In-ovo beskyttelse mod infektiøs bronchitis
CN102382812A (zh) * 2010-12-15 2012-03-21 江苏省家禽科学研究所 传染性支气管炎病毒h120疫苗株反向遗传操作系统及其操作方法
CN102851257A (zh) * 2012-08-27 2013-01-02 上海启盛生物科技有限公司 一种鸡传染性支气管炎病毒减毒疫苗株及其应用
JP6874023B2 (ja) 2016-06-16 2021-05-19 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 伝染性気管支炎ウイルスに対するワクチン

Also Published As

Publication number Publication date
MX2018015506A (es) 2019-05-22
US20170360921A1 (en) 2017-12-21
JP2019521987A (ja) 2019-08-08
JP6874023B2 (ja) 2021-05-19
WO2017216180A1 (en) 2017-12-21
BR112018076234A2 (pt) 2019-03-26
US11065328B2 (en) 2021-07-20
KR20190021334A (ko) 2019-03-05
CN109641043A (zh) 2019-04-16
EA201990010A1 (ru) 2019-07-31
IL263550A (en) 2019-01-31
EP3471769A1 (en) 2019-04-24
CO2019000214A2 (es) 2019-01-18

Similar Documents

Publication Publication Date Title
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
EP4233898A3 (en) Influenza mrna vaccines
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
CL2016000650A1 (es) Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.
BR112016028816A8 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório
PE20151588A1 (es) Vacuna contra el virus del dengue
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
AR080111A1 (es) Metodos y composiciones de inmunizacion
CY1120158T1 (el) Γλουταρυλο ισταμινη για την αγωγη και προφυλαξη παθησεων προκαλουμενων απο ιους που περιεχουν (+)rna
EA201690115A1 (ru) Комбинированные иммуногенные композиции
UY39464A (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
MX2017006744A (es) Composiciones adyuvantes y metodos relacionados.
WO2019068905A3 (en) Feline vaccines conferring early protection
BR112022010147A2 (pt) Vacina tripla contra avibacterium paragallinarum e vírus da encefalomielite aviária e vírus da varíola aviária
CL2015003445A1 (es) Uso del virus de la necrosis nerviosa del jurel (sjnnv) para la protección de peces contra infección por el virus de la necrosis nerviosa del mero de manchas rojas (rgnnv); vacuna que comprende sjnnv; y método para proteger peces contra infección por rgnnv.
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
BR112022007474A2 (pt) Vacina de partículas semelhantes a vírus chikungunya e métodos de uso da mesma
AR115070A1 (es) Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso
AR116878A1 (es) Vacuna de ibv h52 con proteína espicular heteróloga
MX2020003753A (es) Composicion nasal de vacuna contra hepatitis b y metodo para producir la misma.
AR109291A1 (es) Clon de adnc del virus del síndrome reproductivo y respiratorio porcino y usos del mismo
BR112012022680A2 (pt) métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina

Legal Events

Date Code Title Description
FB Suspension of granting procedure